SNU-398人肝癌細(xì)胞（附S
- 公司名稱 上海富雨生物科技有限公司
- 品牌
- 型號(hào)
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2025/2/11 18:16:16
- 訪問(wèn)次數(shù) 92
聯(lián)系方式：陳壽彬18956075901 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息，謝謝!
人肝癌細(xì)胞SNU-398
| 種屬 | 人 |
| 別稱 | SNU398; NCI- SNU- 39 8 |
| 組織來(lái)源 | 肝臟 |
| 疾病 | 肝細(xì)胞癌 |
| 傳代比例/細(xì)胞消化 | 1:2傳代 ，消化1-3分鐘 ， |
| 培養(yǎng)基配置 | RPMI1640 培養(yǎng)基： 10%胎牛血清 ； 1%雙抗 |
| 簡(jiǎn)介 | SNU-398 于 1990 年由 J.-G. Park 及其同事取自一名韓國(guó)患者的間變性肝細(xì)胞癌 ，該患者已通過(guò)脂質(zhì)體加 和-C 的組合進(jìn)行了經(jīng)導(dǎo)管動(dòng)脈栓塞治療。既可以附著細(xì)胞也可以懸浮細(xì)胞。懸浮的細(xì)胞是可行的 ，不應(yīng)丟 棄。通過(guò)溫和離心 (125 xg) 回收懸浮細(xì)胞 ，以與貼壁細(xì)胞群一起進(jìn)行繼代培養(yǎng)。 |
| 形態(tài) | 上皮細(xì)胞樣 |
| 生長(zhǎng)特征 | 懸浮貼壁生長(zhǎng) |
| 倍增時(shí)間 | 每周 2 至 3 次 |
| 抗原表達(dá) | Blood Type O; Rh + |
| STR | Amelogenin: X,Y CSF1PO: 13 D13S317: 11 D16S539: 10, 14 D5S818: 12 D7S820: 10, 11 THO1: 7,9 TPOX:11 vWA: 17, 18 |
| 保藏機(jī)構(gòu) | ATCC; CRL- 2233 |
Background: Hospitals face mounting pressure to reduce unplanned utilization amid rising healthcare demands from an aging population. The Case management for At-Risk patients in the Emergency Department (CARED) program is among the first ED transitional care strategies to focus on both frail older adults and Emergency Department (ED) re-attenders to reduce acute hospital utilization. This study aims to evaluate the effectiveness of the CARED program in reducing hospital (re)admissions and ED re-attendances within 30- and 60-days post-discharge.
Methods: A retrospective, propensity-matched study was conducted from April 2022 to July 2023 in the ED of Ng Teng Fong General Hospital in Singapore. The CARED program identifies and enrols at-risk patients i.e., frail older adults and patients who re-attend the ED within 30 days of hospital discharge, for a geriatric assessment. This is followed by multidisciplinary team care, discharge planning and right siting of care from the ED to community-based services by ED case managers. The primary outcomes were hospital (re)admissions and ED re-attendances within 30- and 60-days post-discharge. Secondary outcomes were cost avoidance and bed occupancy days from reduced acute hospital usage.
untreated host, most aeTSAs are undetected by the immune system. We present evidence suggesting that vaccines inducing direct aeTSA presentation by DCs may represent an attractive strategy for cancer treatment.Checkpoint inhibitors (eg, programmed cell death protein 1 [PD-1], programmed cell death ligａnd 1 [PD-L1], cytotoxic T-lymphocyte associated protein 4 [CTLA-4] antibodies) are changing how we understａnd cancer and provide a means to develop modern
采購(gòu)中心
化工儀器網(wǎng)